Bringing the research sector together to advance the development of novel therapeutics for hearing loss and tinnitus.
Get settled and refreshed before the event begins.
Carla Golledge, whose son was diagnosed with Norrie Disease at birth, will be speaking with Nish Mehta, to share their experience and talk about what treatments would mean to families like hers.
Jane Sowden from University College London will talk about how their team are developing a novel gene therapy that could slow down or even prevent progressive hearing loss in children with Norrie Disease.
Chair: Walter Marcotti, University of Sheffield
Morag Lewis, King’s College London – Identifying candidate therapeutics from transcriptomic data
Jonathan Gale, University College London – Stress granules and their potential as key regulators of hair cell survival
Uri Manor, UC San Diego – Novel Computational and Molecular Imaging Tools for Cochlear Hair Cell Research
Laurent Desire, Sensorion – Developing Novel Gene Therapy for Hereditary Hearing Loss in Patients with GJB2 Mutations
Erik de Vrieze, Radboud University Medical Center – Development of antisense oligonucleotides for the future treatment of dominantly inherited hearing loss
Chair: Charles Large, Autifony Therapeutics
This panel session will explore how early-stage companies and innovators identify, build and maintain productive relationships with potential investors and funders. The panel will also discuss what funders look for when assessing new opportunities.
Panellists include Adam Babbs (Head of Translation, MRC), Hugo Peris (CEO, Spiral Therapeutics), Daniel Ives (CEO, Shift Bioscience) and Elizabeth Klein (Investment Director, Calculus Capital).
In conversation with Derek Hoare, Max Barker will share his experience of living with tinnitus and discuss what he hopes future treatments might look like.
Will Sedley from Newcastle University will join to share his perspective as a clinician scientist on tinnitus treatments currently in development and explore how they might impact people living with the condition.
Chair: Paramita Baruah, University Hospitals of Leicester
Reimar Schlingensiepen, AudioCure – AC102, an NCE Small Molecule in Advanced Stage of Clinical Phase 2 for Sudden Sensorineural Hearing Loss (SSNHL)
Robert Nash, Great Ormond Street Hospital – CHORD: A Phase 1/2 Open-Label, Multi-Center Trial to Evaluate Intracochlear Administration of DB-OTO Gene Therapy in Children with Profound Sensorineural Hearing Loss due to Otoferlin Mutations
Jonas Dyhrfjeld-Johnsen, Acousia Therapeutics – Optimizing Translational Development of the Small Molecule Oto-Protectant ACOU085 for Clinical Proof-Of-Concept
Rachel Haines, Rinri Therapeutics – A Sound Approach: Translating Regenerative Cell Therapy from bench to bedside
Chair: Simon Chandler, Rinri Therapeutics
This session will share updates on two important initiatives focused on regulatory aspects of therapeutic development.
Collen Le Prell, University of Texas at Dallas – Core Outcome Measures for Hearing Therapeutics
Devin Piepert, University of Birmingham – Advancements in Use of Patient Reported Outcomes in Evaluation of Advanced Therapies
Chair: Ralph Holme, RNID
Panel members will reflect upon what they consider to be some of the biggest challenges and opportunities facing the hearing therapeutics sector over the coming years, and what is needed to accelerate progress.
Our sponsors and supporters
An enormous thank you to our sponsors and supporters, without whom this event wouldn’t be possible.
Shionogi
(Gold sponsor)
Acousia
(Silver sponsor)
Sensorion
(Evening reception sponsor)
This meeting was supported by a grant from Norgine who have had no involvement with the organisation or content of the event.
About our sponsors
Acousia Therapeutics
Acousia Therapeutics is a clinical stage biotech company based in Tübingen, Germany, dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss.
Acousia Therapeutics is developing Kv7.4 potassium channel activators (demonstrated to be otoprotective, neuroprotective and mitoprotective along with a capability to modulate amplification/tuning of hearing) for local and systemic administration.
Our most advanced program ACOU085 is a first-in-class, etiology-agnostic otoprotection candidate drug for local delivery through transtympanic injection, currently tested for prevention of hearing loss in testicular cancer patients undergoing cisplatin chemotherapy in our PROHEAR Phase 2a clinical trial.
Shionogi
Shionogi & Co., Ltd. is a 141-year-old global, research driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.”
The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.
For more information on Shionogi & Co., Ltd., please visit their website.
Shionogi B.V. is the European headquarters of Shionogi & Co., Ltd. For more information on Shionogi B.V., please visit the European headquarters website.